Chonnam Med J.  2024 Jan;60(1):78-86. 10.4068/cmj.2024.60.1.78.

Clinical Outcome after Everolimus-Eluting Stent Implantation for Small Vessel Coronary Artery Disease: XIENCE Asia Small Vessel Study

Affiliations
  • 1Department of Cardiovascular Medicine, Chonnam National University Hospital, Gwangju, Korea
  • 2Department of Cardiology, Jeonbuk National University Hospital, Jeonju, Korea
  • 3Department of Cardiology, Chosun University Hospital, Gwangju, Korea
  • 4Department of Cardiology, Wonkwang University Hospital, Iksan, Korea
  • 5Department of Cardiology, Jeju National University Hospital, Jeju, Korea
  • 6Department of Cardiology, KS Hospital, Gwangju, Korea
  • 7Department of Cardiology, Presbyterian Medical Center, Jeonju, Korea
  • 8Department of Cardiology, St. Carollo General Hospital, Suncheon, Korea
  • 9Department of Cardiology, Kwangju Christian Hospital, Gwangju, Korea
  • 10Department of Cardiology, Cheomdan Medical Center, Gwangju, Korea

Abstract

There are limited data on outcomes after implantation of everolimus-eluting stents (EES) in East Asian patients with small vessel coronary lesions. A total of 1,600 patients treated with XIENCE EES (Abbott Vascular, CA, USA) were divided into the small vessel group treated with one ≤2.5 mm stent (n=119) and the non-small vessel group treated with one ≥2.75 mm stent (n=933). The primary end point was a patient-oriented composite outcome (POCO), a composite of all-cause death, myocardial infarction (MI), and any repeat revascularization at 12 months. The key secondary end point was a device-oriented composite outcome (DOCO), a composite of cardiovascular death, target-vessel MI, and target lesion revascularization at 12 months. The small vessel group was more often female, hypertensive, less likely to present with ST-elevation MI, and more often treated for the left circumflex artery, whereas the non-small vessel group more often had type B2/C lesions, underwent intravascular ultrasound, and received unfractionated heparin. In the propensity matched cohort, the mean stent diameter was 2.5±0.0 mm and 3.1±0.4 mm in the small and non-small vessel groups, respectively. Propensity-adjusted POCO at 12 months was 6.0% in the small vessel group and 4.3% in the non-small vessel group (p=0.558). There was no significant difference in DOCO at 12 months (small vessel group: 4.3% and non-small vessel group: 1.7%, p=0.270). Outcomes of XIENCE EES for small vessel disease were comparable to those for non-small vessel disease at 12-month clinical follow-up in real-world Korean patients.

Keyword

Coronary Artery Disease; Drug-Eluting Stents; Everolimus
Full Text Links
  • CMJ
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr